Anniversary Sale Anniversary Sale


Amid Opioid Crisis, Researchers Aim to Put Medical Marijuana to the Test

In a race to address ways to stop the death and destruction that addiction to opioid painkillers is causing across the nation, researchers at UCLA are pitting medical marijuana against opioids to see which works best for pain. This will be the first high-quality study dedicated solely to the study of cannabis with actual opioid patients as study subjects. NBC news said a key part of the study will be to test different combinations of THC and cannabidiol to see which combination works best.

It’s interesting that this medical marijuana study will include various levels of THC — tetrahydrocannabinol — which is the molecule that gives marijuana its psychoactive effects, as we already know that it’s the higher levels of the nonpsychoactive CBD — cannabidiol — that give marijuana its incredible healing properties, mainly from critical levels of medical terpenes and flavonoids. In fact, the powers of CBD are so great that growers have started producing plants with higher CBD and lower THC in them.

It’s been well over three years since then-U.S. Surgeon General Vivek Murthy acknowledged that the government has preliminary data showing support for medical marijuana’s use in certain medical conditions and symptoms. The research is ongoing, but if you talk to Dr. Allan Frankel, a board-certified internist in California, you’ll learn that he has been successfully treating patients with medical marijuana for more than a decade.

In fact, Frankel as personally witnessed tumors in cancer patients virtually disappear, when the patients use no other therapy except to take 40 to 60 milligrams of cannabinoids a day. Other doctors working with medical cannabis are also using it or testing it to treat brain, breast, prostate, lung, thyroid, colon and pituitary cancer, as well as melanoma and leukemia.

As you may very well know, CBD’s curative effects don’t stop with cancer. Even though research has been limited by its classification as a Schedule 1 controlled substance, its list of medicinal benefits is still quite long. From seizures to autism to glaucoma to asthma, multiple sclerosis and, yes, to pain, and more, many different conditions and diseases have responded positively to medical cannabis. The only question is: How many more tests and positive reports do we need for the federal government to release its stranglehold on this product, and take it off the Schedule 1 drug list?